Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Interest of an Attentional Evaluation by a Computerized Battery in the Management of Concussion in Young Rugby Players

NCT05719844 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-03-09
Last updated
2026-04-30

Condition(s) studied

Concussion, Brain

Investigational drug(s) / intervention(s)

Neuropsychological tests

Neuropsychological tests: List of neuropsychological tests: * Matrix reasoning * D2-R * Coding * Symbol search * Digit span * Alertness (computerized TAP battery) * Divided Attention (computerized TAP battery) * Go / No go (computerized TAP battery) * Incompatibility (computerized TAP battery) * Working memory (computerized TAP battery) * 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old) * complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)

Study summary

The goal of this study is to test the ability of a computerized neuropsychological battery to identify attentional disorders resulting from a concussion occurring during the practice of rugby. Thirty young people with a concussion (11-25 years old) will take several neuropsychological tests. Researchers will compare their results with those of young athletes without concussion to see the effect of concussion.

Eligibility

Sex
MALE
Min age
11 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients : * concussion in the context of the practice of rugby * French or reading French without help * Controls : * no concussion * practicing a non-contact sport (athletics, rowing, badminton, capoeira, circus, running, crossfit, cycling, dancing, climbing, fencing, fitness, golf, gymnastics, bodybuilding, swimming, skating, Qi Gong, Taï chi, tennis, table tennis, shooting, trail running, volleyball, water polo) within a sports association * age matched to patient (+/- 1 year) * study level matched to patient (+/- 1 year) * French or reading French without help Exclusion Criteria: * Patients : * Legal protection measure * Other neurological or psychiatric pathologies prior to concussion episodes * Diagnosis of a neurodevelopmental disorder in childhood * Score less than or equal to 5/19 on the "Matrix" subtest (intellectual retardation) * Addictive behaviors * Current major depressive disorder or treated with antidepressants or benzodiazepines for less than 3 months * Severe visual or motor problems that may interfere with the performance of the tests * Controls : * Legal protection measure * History of proven concussion * Other neurological or psychiatric pathologies * Diagnosis of a neurodevelopmental disorder in childhood * Score less than or equal to 5/19 on the "Matrix" subtest (intellectual retardation) * Addictive behaviors * Current major depressive episode or treated with antidepressants or benzodiazepines for less than 3 months * Severe visual or motor problems that may interfere with the performance of the tests

Primary outcome measure(s)

  • Alertness time — At inclusion
    Reaction time (ms) in the Alertness TAP test
  • Alertness error — At inclusion
    Number of errors in the Alertness TAP test
  • Divided Attention time — At inclusion
    Reaction time (ms) in the Divided Attention TAP test
  • Divided Attention error — At inclusion
    Number of errors in the Divided Attention TAP test
  • Go/No-go time — At inclusion
    Reaction time (ms) in the Go/No-go TAP test
  • Go/No-go error — At inclusion
    Number of errors in the Go/No-go TAP test
  • Incompatibility time — At inclusion
    Reaction time (ms) in the Incompatibility TAP test
  • Incompatibility error — At inclusion
    Number of errors in the Incompatibility TAP test
  • Working Memory time — At inclusion
    Reaction time (ms) in the Working Memory TAP test
  • Working Memory error — At inclusion
    Number of errors in the Working Memory TAP test

Trial sites (1)

FacilityCityRegionStatus
CHU de Clermont-Ferrand Clermont-Ferrand France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05719844 on ClinicalTrials.gov ↗ ← All trials in France